Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911524 | 0.86 | HTT (0.51) | TSHRHTTCNR2KMT2ALMNA | |
| SCHEMBL14911407 | 0.83 | KMT2A (0.51) | HPGDGRM2RAD51CNR2KMT2A | |
| SCHEMBL20964396 | 0.79 | HPGD (0.36) | HPGDTSHRHTTRAD51CNR2 | |
| SCHEMBL14911499 | 0.75 | PDE8B (0.44) | HPGDRAD51CNR2 | |
| SCHEMBL20968378 | 0.74 | TSHR (0.42) | HPGDTSHRRAD51CNR2KMT2A | |
| SCHEMBL17731791 | 0.73 | CNR2 (0.43) | CNR2 | |
| SCHEMBL19743667 | 0.72 | CNR2 (0.44) | CNR2 | |
| SCHEMBL19743706 | 0.70 | HPGD (0.40) | HPGDTSHRHTTRAD51CNR2 | |
| SCHEMBL19744103 | 0.66 | HPGD (0.36) | HPGDTSHRHTTCNR2KMT2A | |
| SCHEMBL19743563 | 0.65 | RAD51 (0.44) | HPGDRAD51CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475280-B1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3475280-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220516-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | HPGD 1645/4885TSHR 838/4885GRM2 1681/4885 |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | TYMS, DPYD, TYMP | HPGD 1044/4885TSHR 656/4885GRM2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.